NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tectonic Therapeutic, Inc. (TECX) Stock Analysis

Tectonic Therapeutic, Inc. (TECX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TECX

$21.84

+$0.02 (+0.07%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TECX with… →

TECX Key Statistics

As of Oct 21, 2026
Trading
Open
$21.86
Previous Close
$21.83
Day's Range
21.53–22.28
52-Week Range
15.52–39.53
Volume
152.83K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$426.96M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.57
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$74.15M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.55M
1-Year Return
+15.01%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
216.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TECX closed at $21.84, +15.01% over 1 year.

Tectonic Therapeutic, Inc. (TECX) has a market capitalization of $426.96M.

In fiscal 2025, TECX reported revenue of $0.00.

TECX Stock Return by Calendar Year

Tectonic Therapeutic, Inc. (TECX) return since Jun 2018: what $10,000 became

1 year
$10,000 $11,501
+15.01%
5 years
$10,000 $3,285
−67.15%
Since Jun 2018
$10,000 $583
−94.17%

If you had invested $10,000 in Tectonic Therapeutic, Inc. (TECX) at the close on June 21, 2018, the earliest close on record here, it would have been worth $583 at the close on October 21, 2026: −94.17% in total, −28.89% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4.70%
2025−54.82%
2024+182.90%
2023+91.55%
2022−81.56%
2021−72.38%
2020−30.75%
2019+20.90%
2018 (partial year)−46.63%

As of October 21, 2026.

TECX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$74.15M—
2024$0.00−$57.98M—
2023$0.00−$42.82M—
2022$0.00−$32.18M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.04M−$74.15M—
2024$0.00—−$58.02M−$57.98M—
2023$0.00—−$44.65M−$42.82M—
2022$0.00—−$32.83M−$32.18M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tectonic Therapeutic, Inc. (TECX) carries a market capitalisation of $426.96M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 60.

TECX last closed at $21.84 on October 21, 2026. That is +$0.02 (+0.07%) against the previous close. The 52-week range on file runs from $15.52 to $39.53. The latest close sits 40.72% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $74.15M. Trailing earnings per share are −4.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is +15.01%. Across 5 years the annualized return works out at −19.96%. Beta against the wider market is reported at 0.38. Annualized volatility over the trailing 8 years is 386.53%.

Growth & Income

The record shows no dividend for TECX.

2026 is still running; the total return is +4.70% year to date. The strongest complete calendar year on file is 2024 at +182.90%; the weakest is 2022 at −81.56%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Tectonic Therapeutic, Inc. (TECX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tectonic Therapeutic, Inc. TECX $426.96M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tectonic Therapeutic, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Visit website →